OLA Blog

MAREMAR STUDY: HOW CKD EPIDEMIOLOGY SHOULD BE CONDUCTED!

Written by Meguid El Nahas on Monday, 25 April 2016. Posted in OLA Blog

MAREMAR STUDY: HOW CKD EPIDEMIOLOGY SHOULD BE CONDUCTED!
MAREMAR STUDY: CKD CLASSIFICATION, TIME TO RE-THINK?   https://www.researchgate.net/publication/297892002_Maremar_prevalence_of_chronic_kidney_disease_how_to_avoid_over-diagnosis_and_under-diagnosis   The MAREMAR study of CKD...

Obesity and Diabetes: A Myth?

Written by Meguid El Nahas on Sunday, 24 April 2016. Posted in OLA Blog

Obesity and Diabetes: A Myth?
http://www.ncbi.nlm.nih.gov/pubmed/27061677 The latest analysis by the Non-Communicable Disease worldwide collaboration gives an intriguing picture of the prevalence of Diabetes Mellitus (DM) worldwide. Age-standardised prevalence, shows: NO...

A CKD CLASSIFICATION FOR ALL AGES!?

Written by Meguid El Nahas on Wednesday, 13 April 2016. Posted in OLA Blog

A CKD CLASSIFICATION FOR ALL AGES!?
http://www.ncbi.nlm.nih.gov/pubmed/27057075 This excellent paper proposes an age-sensitive CKD classification: <40 years: CKD threshold = 75 ml/min 40-65years: CKD threshold = 60 ml/min >65 years: CKD threshold =45 ml/min this in the...

ARE SCIENTIFIC JOURNALS FIT FOR PURPOSE?

Written by Meguid El Nahas on Sunday, 10 April 2016. Posted in OLA Blog

ARE SCIENTIFIC JOURNALS FIT FOR PURPOSE?
This is an interesting blog by Dr Ben Goldacre who basically is arguing that academic journals are effectively not a 'fit for purpose' arena to publish results of clinical trials.   He also makes the point that the usually impossible to get...

HLA incompatible live transplantation

Written by arif khwaja on Friday, 08 April 2016. Posted in OLA Blog

HLA incompatible live  transplantation
Whilst the benefits of transplantation are well established, finding suitable donors for ‘sensitised’ patients with anti-HLA antibodies remains a significant barrier to transplantation. The options for such patients are to stay on the...

Thrombotic Microangiopathies

Written by Neveen A Soliman on Tuesday, 29 March 2016. Posted in OLA Blog

Thrombotic Microangiopathies
  Enormous advances continue to be made to enhance our understanding of the challenging “thrombotic microangiopathies TMA” It is becoming clear, recently, that distinct disease mechanisms underlie the group of diseases formerly...

No Profit...No CKD...

Written by Meguid El Nahas on Monday, 14 March 2016. Posted in OLA Blog

No Profit...No CKD...
I received this letter from a US Nephrologist working in non fee for service environment... revealing! Hello Professor Meguid El Nahas,  I saw your article in Jama from August 2015, regarding CKD...

AKI in the UK: From 1998-2013

Written by Meguid El Nahas on Wednesday, 02 March 2016. Posted in OLA Blog

AKI in the UK: From 1998-2013
Kidney Int. 2015 Nov;88(5):1161-9. doi: 10.1038/ki.2015.234. Epub 2015 Jul 29. National trends in acute kidney injury requiring dialysis in England between 1998 and 2013. Kolhe NV1, Muirhead AW2, Wilkes...

SPRINT: NOT SO FAST...

Written by Meguid El Nahas on Sunday, 17 January 2016. Posted in OLA Blog

SPRINT: NOT SO FAST...
N Engl J Med. 2015 Nov 26;373(22):2103-16. doi: 10.1056/NEJMoa1511939. Epub 2015 Nov 9. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. SPRINT Research Group, Wright JT Jr, Williamson...

BREAKING NEWS! FDA Adds New Warnings on SGLT2 Inhibitors

Written by Jose Mario Franco de Oliveira on Saturday, 05 December 2015. Posted in OLA Blog

BREAKING  NEWS! FDA Adds New Warnings on SGLT2  Inhibitors
http://www.medpagetoday.com/Endocrinology/Diabetes/55035?isalert=1&uun=g257073d4708R5252063u&xid=NL_breakingnews_2015-12-04 EMPAGLIFLOZIN, CANAGLIFLOZIN, DAPAGLIFLOZIN, the so-called SGLT2 Inhbitors so far in the market (and others are...